{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:03:00Z","timestamp":1791424980327,"version":"4.3.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007241","name":"Universit\u00e9 Paris-Saclay","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40262-025-01562-9","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T10:07:59Z","timestamp":1758103679000},"page":"1709-1722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Modeling Whole-Body Dynamic PET Microdosing Data to Predict the Whole-Body Pharmacokinetics of Glyburide in Humans"],"prefix":"10.1007","volume":"64","author":[{"given":"L\u00e9a","family":"Comin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Marie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno","family":"Ursino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9150-9886","authenticated-orcid":false,"given":"Emmanuelle","family":"Comets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"1562_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104238","volume":"29","author":"A Himstedt","year":"2024","unstructured":"Himstedt A, Rapp H, Stopfer P, Lotz R, Scheuerer S, Arnhold T, et al. Beyond CL and VSS: a comprehensive approach to human pharmacokinetic predictions. Drug Discov Today. 2024;29: 104238.","journal-title":"Drug Discov Today"},{"key":"1562_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12967-019-1976-2","volume":"17","author":"CHC Leenaars","year":"2019","unstructured":"Leenaars CHC, Kouwenaar C, Stafleu FR, Bleich A, Ritskes-Hoitinga M, De Vries RBM, et al. Animal to human translation: a systematic scoping review of reported concordance rates. J Transl Med. 2019;17:223.","journal-title":"J Transl Med"},{"key":"1562_CR3","unstructured":"Dw van V, Ehj K, Caj K. All you need to know about allometric scaling: an integrative review on the theoretical basis, empirical evidence, and application in human pharmacology. Clin Pharmacokinet [Internet]. 2025 [cited 2025 Mar 20];64. https:\/\/pubmed.ncbi.nlm.nih.gov\/39644458\/"},{"key":"1562_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41573-020-0080-x","volume":"19","author":"T Burt","year":"2020","unstructured":"Burt T, Young G, Lee W, Kusuhara H, Langer O, Rowland M, et al. Phase 0\/microdosing approaches: time for mainstream application in drug development? Nat Rev Drug Discov. 2020;19:801\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"1562_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.pharmthera.2018.04.006","volume":"189","author":"N Tournier","year":"2018","unstructured":"Tournier N, Stieger B, Langer O. Imaging techniques to study drug transporter function in vivo. Pharmacol Ther. 2018;189:104\u201322.","journal-title":"Pharmacol Ther"},{"key":"1562_CR6","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1016\/j.apsb.2025.03.030","volume":"15","author":"S Marie","year":"2025","unstructured":"Marie S, Lecoq A-L, Breuil L, Caill\u00e9 F, Lebon V, Comtat C, et al. Imaging the impact of sex and age on OATP function in humans: consequences for whole-body pharmacokinetics and liver exposure. Acta Pharm Sin B. 2025;15:2736\u201345.","journal-title":"Acta Pharm Sin B"},{"key":"1562_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113994","volume":"156","author":"S Marie","year":"2022","unstructured":"Marie S, Breuil L, Chalampalakis Z, Becquemont L, Verstuyft C, Lecoq A-L, et al. [11C]glyburide PET imaging for quantitative determination of the importance of organic anion-transporting polypeptide transporter function in the human liver and whole-body. Biomed Pharmacother. 2022;156: 113994.","journal-title":"Biomed Pharmacother"},{"key":"1562_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113994","volume":"156","author":"S Marie","year":"2022","unstructured":"Marie S, Breuil L, Chalampalakis Z, Becquemont L, Verstuyft C, Lecoq A-L, et al. [11C]glyburide PET imaging for quantitative determination of the importance of organic anion-transporting polypeptide transporter function in the human liver and whole-body. Biomed Pharmacother Biomedecine Pharmacother. 2022;156: 113994.","journal-title":"Biomed Pharmacother Biomedecine Pharmacother."},{"key":"1562_CR9","unstructured":"Marie S, Lecoq A-L, Breuil L, Caill\u00e9 F, Lebon V, Comtat C, et al. Imaging the impact of sex and age on OATP function in humans: consequences for whole-body pharmacokinetics and liver exposure. Acta Pharm Sin B [Internet]. 2025 [cited 2025 Mar 19]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2211383525001698"},{"key":"1562_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28030931","volume":"28","author":"A Pees","year":"2023","unstructured":"Pees A, Chass\u00e9 M, Lindberg A, Vasdev N. Recent developments in carbon-11 chemistry and applications for first-in-human PET studies. Molecules. 2023;28: 931.","journal-title":"Molecules"},{"key":"1562_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0091270007311569","volume":"48","author":"A Kalliokoski","year":"2008","unstructured":"Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol. 2008;48:311\u201321.","journal-title":"J Clin Pharmacol"},{"key":"1562_CR12","doi-asserted-by":"crossref","unstructured":"SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008;359:789\u201399.","DOI":"10.1056\/NEJMoa0801936"},{"key":"1562_CR13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1742-7843.2010.00581.x","volume":"107","author":"A Kalliokoski","year":"2010","unstructured":"Kalliokoski A, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol. 2010;107:775\u201381.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1562_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11222-013-9396-2","volume":"24","author":"M Lavielle","year":"2014","unstructured":"Lavielle M, Mbogning C. An improved SAEM algorithm for maximum likelihood estimation in mixtures of non linear mixed effects models. Stat Comput. 2014;24:693\u2013707.","journal-title":"Stat Comput"},{"key":"1562_CR15","doi-asserted-by":"publisher","unstructured":"Delattre M, Lavielle M, Poursat M-A. A note on BIC in mixed-effects models. Electron J Stat [Internet]. 2014 [cited 2025 Mar 20];8. Available from: https:\/\/projecteuclid.org\/journals\/electronic-journal-of-statistics\/volume-8\/issue-1\/A-note-on-BIC-in-mixed-effects-models\/https:\/\/doi.org\/10.1214\/14-EJS890.full","DOI":"10.1214\/14-EJS890.full"},{"key":"1562_CR16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/psp4.12612","volume":"10","author":"G Ayral","year":"2021","unstructured":"Ayral G, Si Abdallah J-F, Magnard C, Chauvin J. A novel method based on unbiased correlations tests for covariate selection in nonlinear mixed effects models: the COSSAC approach. CPT Pharmacomet Syst Pharmacol. 2021;10:318\u201329.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1562_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351.","journal-title":"AAPS J"},{"key":"1562_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1208\/s12248-021-00597-7","volume":"23","author":"E Comets","year":"2021","unstructured":"Comets E, Mentr\u00e9 F. Developing tools to evaluate non-linear mixed effect models: 20 years on the NPDE adventure. AAPS J. 2021;23:75.","journal-title":"AAPS J"},{"key":"1562_CR19","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","volume":"27","author":"RB Innis","year":"2007","unstructured":"Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533\u20139.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1562_CR20","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s00259-024-06640-x","volume":"51","author":"C Stokke","year":"2024","unstructured":"Stokke C, Gnesin S, Tran-Gia J, Cicone F, Holm S, Cremonesi M, et al. EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials. Eur J Nucl Med Mol Imaging. 2024;51:1268\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1562_CR21","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/cpt.3564","volume":"117","author":"MVS Varma","year":"2025","unstructured":"Varma MVS, Vourvahis M. Navigating the challenges of cyclosporine as an alternative to rifampicin as an OATP1B index inhibitor. Clin Pharmacol Ther. 2025;117(5):1175\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1562_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"International Transporter Consortium, Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215\u201336.","journal-title":"Nat Rev Drug Discov"},{"key":"1562_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/clpt.2008.186","volume":"85","author":"HX Zheng","year":"2009","unstructured":"Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin\u2019s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009;85:78\u201385.","journal-title":"Clin Pharmacol Ther"},{"key":"1562_CR24","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/0002-9343(90)90330-G","volume":"89","author":"AE Boyd","year":"1990","unstructured":"Boyd AE, Aguilar-Bryan L, Nelson DA. Molecular mechanisms of action of glyburide on the beta cell. Am J Med. 1990;89:S3-10.","journal-title":"Am J Med"},{"key":"1562_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s005920050081","volume":"34","author":"L Luzi","year":"1997","unstructured":"Luzi L, Pozza G. Glibenclamide: an old drug with a novel mechanism of action? Acta Diabetol. 1997;34:239\u201344.","journal-title":"Acta Diabetol"},{"key":"1562_CR26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/cpt.3123","volume":"115","author":"M Yin","year":"2024","unstructured":"Yin M, Balhara A, Marie S, Tournier N, G\u00e1borik Z, Unadkat JD. Successful prediction of human hepatic concentrations of transported drugs using the proteomics-informed relative expression factor approach. Clin Pharmacol Ther. 2024;115:595\u2013605.","journal-title":"Clin Pharmacol Ther"},{"key":"1562_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1124\/dmd.116.074815","volume":"45","author":"R Li","year":"2017","unstructured":"Li R, Bi Y-A, Vildhede A, Scialis RJ, Mathialagan S, Yang X, et al. Transporter-mediated disposition, clinical pharmacokinetics and cholestatic potential of glyburide and its primary active metabolites. Drug Metab Dispos. 2017;45:737\u201347.","journal-title":"Drug Metab Dispos"},{"key":"1562_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711\u201326.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1562_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2125.1997.00571.x","volume":"43","author":"T Rydberg","year":"1997","unstructured":"Rydberg T, J\u00f6nsson A, Karlsson MO, Melander A. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1997;43:373\u201381.","journal-title":"Br J Clin Pharmacol"},{"key":"1562_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105380","volume":"151","author":"L Klumpp","year":"2020","unstructured":"Klumpp L, Dressman J. Physiologically based pharmacokinetic model outputs depend on dissolution data and their input: case examples glibenclamide and dipyridamole. Eur J Pharm Sci. 2020;151: 105380.","journal-title":"Eur J Pharm Sci"},{"key":"1562_CR31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.ejps.2013.06.009","volume":"49","author":"R Greupink","year":"2013","unstructured":"Greupink R, Schreurs M, Benne MS, Huisman MT, Russel FGM. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. Eur J Pharm Sci. 2013;49:819\u201328.","journal-title":"Eur J Pharm Sci"},{"key":"1562_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70006","author":"S van der Gaag","year":"2025","unstructured":"van der Gaag S, Jordens T, Yaqub M, Grijseels R, van Valkengoed DW, de Langen EN, et al. Physiologically based pharmacokinetic model of tyrosine kinase inhibitors to predict target site penetration, with PET-guided verification. CPT Pharmacometrics Syst Pharmacol. 2025. https:\/\/doi.org\/10.1002\/psp4.70006.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1562_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/psp4.12787","volume":"11","author":"JR Wedagedera","year":"2022","unstructured":"Wedagedera JR, Afuape A, Chirumamilla SK, Momiji H, Leary R, Dunlavey M, et al. Population PBPK modeling using parametric and nonparametric methods of the Simcyp simulator, and Bayesian samplers. CPT Pharmacomet Syst Pharmacol. 2022;11:755\u201365.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1562_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1478-5382(03)02342-4","volume":"1","author":"S Willmann","year":"2003","unstructured":"Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W. PK-Sim\u00ae: a physiologically based pharmacokinetic \u201cwhole-body\u201d model. Biosilico. 2003;1:121\u20134.","journal-title":"Biosilico"},{"key":"1562_CR35","unstructured":"Teutonico D, Marchionni D, Lavielle M, Nguyen L. Estimation of population parameter values and variability coupling non-linear mixed-effects modeling (based on SAEM algorithm) with a whole-body PBPK model. 24th meeting of the Population Approach Group in Europe, Rome. 2024; https:\/\/www.page-meeting.org\/default.asp?abstract=11055"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01562-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01562-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01562-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:03:47Z","timestamp":1763168627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01562-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1562"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01562-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L\u00e9a Comin, Sol\u00e8ne Marie, Moreno Ursino, Sarah Zohar, Nicolas Tournier, and Emmanuelle Comets have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by an ethics committee (CPP IDF5: 17041, study reg. no. EudraCT 2017-001703-69).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}